NCT07162441View on ClinicalTrials.gov

A Two-arm, Open-label, Single-sequence, Multiple-dose, Cross-over Study to Evaluate the Pharmacokinetic Interaction and the Safety of UIC202502 and UIC202505 in Healthy Adult Volunteers

PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 12, 2025

Primary Completion Date

September 30, 2025

Study Completion Date

March 1, 2026

Conditions
Dyslipidemia
Interventions
DRUG

treatment A

UIC202502 1 Tab/day for 7 days

DRUG

treatment B

UIC202505 1 Tab/day for 7 days

DRUG

treatment C

UIC202502+UIC202505 2 Tab/day for 7 days

Trial Locations (1)

08779

RECRUITING

H plus Yangji Hospital, Seoul

All Listed Sponsors
lead

Korea United Pharm. Inc.

INDUSTRY